The dynamical evolution of the circumstellar gas around low-and intermediate-mass stars I: the AGB

We have investigated the dynamical interaction of low- and-intermediate mass stars (from 1 to 5 Msun) with their interstellar medium (ISM). In this first paper, we examine the structures generated by the stellar winds during the Asymptotic Giant Branch (AGB) phase, using a numerical code and the wind history predicted by stellar evolution. The influence of the external ISM is also taken into account. We find that the wind variations associated with the thermal pulses lead to the formation of transient shells with an average lifetime of 20,000 yr, and consequently do not remain recorded in the density or velocity structure of the gas. The formation of shells that survive at the end of the AGB occurs via two main processes: shocks between the shells formed by two consecutive enhancements of the mass-loss or via continuous accumulation of the material ejected by the star in the interaction region with the ISM. Our models show that the mass of the circumstellar envelope increases appreciably due to the ISM material swept up by the wind (up to 70 % for the 1 Msun stellar model). We also point out the importance of the ISM on the deceleration and compression of the external shells. According to our simulations, large regions (up to 2.5 pc) of neutral gas surrounding the molecular envelopes of AGB stars are expected. These large regions of gas are formed from the mass-loss experienced by the star during the AGB evolution.Comment: 43 pages, 15 figures. Accepted for publication in the Astrophysical Journa

Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data

Background: Patients who have had a stroke with unknown time of onset have been previously excluded from thrombolysis. We aimed to establish whether intravenous alteplase is safe and effective in such patients when salvageable tissue has been identified with imaging biomarkers. Methods: We did a systematic review and meta-analysis of individual patient data for trials published before Sept 21, 2020. Randomised trials of intravenous alteplase versus standard of care or placebo in adults with stroke with unknown time of onset with perfusion-diffusion MRI, perfusion CT, or MRI with diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR) mismatch were eligible. The primary outcome was favourable functional outcome (score of 0–1 on the modified Rankin Scale [mRS]) at 90 days indicating no disability using an unconditional mixed-effect logistic-regression model fitted to estimate the treatment effect. Secondary outcomes were mRS shift towards a better functional outcome and independent outcome (mRS 0–2) at 90 days. Safety outcomes included death, severe disability or death (mRS score 4–6), and symptomatic intracranial haemorrhage. This study is registered with PROSPERO, CRD42020166903. Findings: Of 249 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THAWS, and ECASS-4. The four trials provided individual patient data for 843 individuals, of whom 429 (51%) were assigned to alteplase and 414 (49%) to placebo or standard care. A favourable outcome occurred in 199 (47%) of 420 patients with alteplase and in 160 (39%) of 409 patients among controls (adjusted odds ratio [OR] 1·49 [95% CI 1·10–2·03]; p=0·011), with low heterogeneity across studies (I2=27%). Alteplase was associated with a significant shift towards better functional outcome (adjusted common OR 1·38 [95% CI 1·05–1·80]; p=0·019), and a higher odds of independent outcome (adjusted OR 1·50 [1·06–2·12]; p=0·022). In the alteplase group, 90 (21%) patients were severely disabled or died (mRS score 4–6), compared with 102 (25%) patients in the control group (adjusted OR 0·76 [0·52–1·11]; p=0·15). 27 (6%) patients died in the alteplase group and 14 (3%) patients died among controls (adjusted OR 2·06 [1·03–4·09]; p=0·040). The prevalence of symptomatic intracranial haemorrhage was higher in the alteplase group than among controls (11 [3%] vs two [<1%], adjusted OR 5·58 [1·22–25·50]; p=0·024). Interpretation: In patients who have had a stroke with unknown time of onset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outcome at 90 days than placebo or standard care. A net benefit was observed for all functional outcomes despite an increased risk of symptomatic intracranial haemorrhage. Although there were more deaths with alteplase than placebo, there were fewer cases of severe disability or death. Funding: None

Ritual Dynamics and Religious Change in the Roman Empire. Proceedings of the Eighth Workshop of the International Network Impact of Empire (Heidelberg, July 5-7, 2007)

Item does not contain fulltext377 p

Preface

Contains fulltext : 104468.pdf (publisher's version ) (Closed access)Eighth Workshop of the International Network Impact of Empire, 5 juli 2007377 p

J/ψ production via χc decays in 920 GeV pA interactions

Using data collected by the HERA-B experiment, we have measured the fraction of J/ψ’s produced via radiative χc decays in interactions of 920 GeV protons with carbon and titanium targets. We obtained Rχc = 0.32 ± 0.06stat ± 0.04sys for the fraction of J/ψ from χc decays averaged over proton–carbon and proton–titanium collisions. This result is in agreement with previous measurements and is compared with theoretical prediction